XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

XPOVIO® (selinexor) is the only oral therapy indicated for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL). Credit: Karyopharm Therapeutics Inc.



  • XPOVIO (selinexor)
  • XPOVIO (selinexor)
  • XPOVIO (selinexor)